City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine
By Amit Chowdhry ● Oct 8, 2024
City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger” molecules that mediate RNAi – to build a robust and sustainable product engine and expand the therapeutic reach of RNAi-based medicines. Headed by executive chair John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, the company has completed a $135 million Series A financing led by ARCH Venture Partners, with participation from other leading life sciences investors including Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and other undisclosed investors.